CASM - CAS Medical Systems, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.14
-0.03 (-2.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.17
Open1.16
Bid1.10 x 100
Ask1.18 x 1000
Day's Range1.10 - 1.18
52 Week Range0.59 - 1.35
Volume42,265
Avg. Volume21,826
Market Cap31.268M
Beta-0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateMay 1, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research25 days ago

    CASM: Q4 2017 Financial Results: Record Revenue, Lowest Op Loss. Momentum Expected to Continue

    CAS Medical (CASM) reported financial results for Q4 2017, which saw revenue well ahead of our pre-preliminary announcement numbers (CASM pre-announced Q4 in early January). Strength in the U.S. market, which has been attributed to a combination of catalysts, more than offset a double-digit decline in international sales and pushed total FORE-SIGHT revenue to an all-time high. Indications, which includes 2018 guidance of low-teens percentage increase in U.S. FORE-SIGHT revenue, are that this momentum will continue, and potentially accelerate.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CASM earnings conference call or presentation 14-Mar-18 2:00pm GMT

    Q4 2017 CAS Medical Systems Inc Earnings Call

  • GlobeNewswirelast month

    CASMED Reports 2017 Fourth-Quarter and Full-Year Financial Results

    FORE-SIGHT sales increased 18% in Q4 on record 80 placements. Conference Call Begins Today at 10:00 a.m. Eastern Time. BRANFORD, Conn., March 14, 2018-- CAS Medical Systems, Inc., a leader in medical products ...

  • GlobeNewswirelast month

    CASMED to Report Fourth-Quarter and 2017 Full-Year Financial Results and Hold Conference Call on March 14

    BRANFORD, Conn., March 07, 2018-- CAS Medical Systems, Inc., a leader in medical devices for non-invasive patient monitoring, announces that it will report financial results for the fourth quarter and ...

  • What does CAS Medical Systems Inc’s (NASDAQ:CASM) Balance Sheet Tell Us About Its Future?
    Simply Wall St.2 months ago

    What does CAS Medical Systems Inc’s (NASDAQ:CASM) Balance Sheet Tell Us About Its Future?

    CAS Medical Systems Inc (NASDAQ:CASM) is a small-cap stock with a market capitalization of US$31.44M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • GlobeNewswire3 months ago

    CASMED Submits FORE-SIGHT® OEM Module 510(k) to FDA

    BRANFORD, Conn., Jan. 24, 2018-- CAS Medical Systems, Inc., a leader in non-invasive cerebral oximetry patient monitoring, announces that it has submitted a 510 application to the U.S. Food and Drug Administration ...

  • CAS Medical Systems, Inc. :CASM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
    Capital Cube5 months ago

    CAS Medical Systems, Inc. :CASM-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017

    Categories: Yahoo FinanceGet free summary analysis CAS Medical Systems, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of CAS Medical Systems, Inc. – NeuroMetrix, Inc., Utah Medical Products, Inc., Royal Philips NV Sponsored ADR, Masimo Corporation and General Electric Company (NURO-US, UTMD-US, PHG-US, MASI-US and ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CASM earnings conference call or presentation 9-Nov-17 3:00pm GMT

    Q3 2017 CAS Medical Systems Inc Earnings Call

  • Zacks Small Cap Research5 months ago

    CASM: Operational Successes Bode Well For Restarting Sensors Sales Growth

    U.S. FORE-SIGHT sales not only returned to growth (+2% yoy and +5% qoq) in Q3, but at $3.8M, set a new record high.  But, with tissue oximetry sales falling by almost 9% yoy and roughly flat sequentially, it was far from a strong quarter as it relates to financial results.  The lack of top-line growth has recently been impacted by softness in China (as that country awaits CFDA approval of FORE-SIGHT ELITE) but remains largely tied to absence of traction in sensor sales, which account for more than 90% of tissue oximetry revenue.  As we have indicated in previous updates, the lack of sensor-related revenue growth in the face of an ever-larger monitor installed base is somewhat anomalistic, in our opinion. As it relates to the sales force, turnover has meant average tenure (and related productivity) decreased – but on the (more recent) positive side, management indicated that overall productivity has improved and sensor-related revenue growth among the more tenured reps has been relatively very strong (which could be a harbinger of maturation-correlated productivity gains among the less tenured).

  • Capital Cube5 months ago

    ETFs with exposure to CAS Medical Systems, Inc. : November 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CAS Medical Systems, Inc. Here are 5 ETFs with the largest exposure to CASM-US. Comparing the performance and risk of CAS Medical Systems, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Should Your Next Investment In The Healthcare Industry Be In CAS Medical Systems Inc (CASM)?
    Simply Wall St.5 months ago

    Should Your Next Investment In The Healthcare Industry Be In CAS Medical Systems Inc (CASM)?

    CAS Medical Systems Inc (NASDAQ:CASM), a USD$20.77M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population andRead More...

  • How Financially Strong Is CAS Medical Systems Inc (CASM)?
    Simply Wall St.6 months ago

    How Financially Strong Is CAS Medical Systems Inc (CASM)?

    While small-cap stocks, such as CAS Medical Systems Inc (NASDAQ:CASM) with its market cap of USD $20.77M, are popular for their explosive growth, investors should also be aware of theirRead More...

  • Capital Cube6 months ago

    ETFs with exposure to CAS Medical Systems, Inc. : October 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CAS Medical Systems, Inc. Here are 5 ETFs with the largest exposure to CASM-US. Comparing the performance and risk of CAS Medical Systems, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CASM earnings conference call or presentation 9-Mar-17 3:00pm GMT

    Q4 2016 CAS Medical Systems Inc Earnings Call

  • Capital Cube7 months ago

    ETFs with exposure to CAS Medical Systems, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CAS Medical Systems, Inc. Here are 5 ETFs with the largest exposure to CASM-US. Comparing the performance and risk of CAS Medical Systems, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • CAS Medical Systems, Inc. :CASM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
    Capital Cube7 months ago

    CAS Medical Systems, Inc. :CASM-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017

    Categories: Yahoo FinanceGet free summary analysis CAS Medical Systems, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of CAS Medical Systems, Inc. – MGC Diagnostics Corporation, Utah Medical Products, Inc., Royal Philips NV Sponsored ADR and Masimo Corporation (MGCD-US, UTMD-US, PHG-US and MASI-US) that have ... Read more (Read more...)

  • Zacks Small Cap Research8 months ago

    CASM: Clinical Superiority, Productivity Gains Bode Well For Growth Inflection

    The clinical superiority is further supported by the 75% - 85% new customer close rate when prospective clinicians perform a clinical evaluation of FORE-SIGHT.  Management noted that through the twelve months ending 6/30/17, 40% of monitor placements reflect market share gains (i.e.